Multidrug-resistant Candida auris: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies

Image of Continuing Education Credits abbreviation. = Free Continuing Education

Date: Thursday, June 20, 2019

Time: 2:00pm-3:00pm (Eastern Time)

Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-062019—(Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “Multi-drug Resistant Candida auris: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies” Thursday, June 20, 2019, please visit TCEO and follow these 9 Simple Steps by July 22, 2019.

To receive continuing education (CE) for WD2922-062019—(Web on demand) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “Multi-drug Resistant Candida auris: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies” Thursday, June 20, 2019, please visit TCEO and follow these 9 Simple Steps by July 23, 2021.

Overview

Candida auris (C. auris) is an emerging fungus that presents a serious global health threat. CDC is concerned about C. auris for 3 main reasons:

  1. It is often multidrug-resistant, meaning multiple antifungal drugs are less or not at all effective in treating C. auris.
  2. It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate management.
  3. It has caused outbreaks in healthcare settings. It is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.

Most C. auris cases in the United States have been detected in the New York City area, New Jersey, and the Chicago area. Clusters of cases have also recently been described in Florida, Texas, and California. C. auris cases in the United States are originally a result of inadvertent introduction into the United States from a patient who had received healthcare in a country where C. auris has been reported.  Most cases now are a result of local spread after such an introduction.

During this COCA Call, CDC presenters will

  • Provide an update on the current status of auris
  • Explain why it is a public health threat
  • Review current U.S. epidemiology and resistance patterns to antifungal drugs
  • Discuss clinical considerations when treating patients for auris
  • Lay out steps for identifying and controlling C. auris.

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.

Activity Specific Objectives:
At the conclusion of the session, the participant will be able to accomplish the following:

  • Describe risk factors for C. auris infection and colonization.
  • Discuss resistance patterns in C. auris.
  • Describe evolving treatment options for C. auris.
  • Define steps to take when a case of C. auris is suspected or identified.

Snigdha Vallabhaneni, MD, MPH
Medical Epidemiologist, Prevention and Response Branch
Division of Healthcare Quality Promotion
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Tom Chiller, MD, MPH
Chief, Mycotic Diseases Branch
Division of Foodborne, Waterborne, and Environmental Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

  • Webinar/Audio conference call on Thursday, June 20, 2019: 2:00 – 3:00 PM ET
  • Web-on-demand training will be available a few days after the live call.

A few minutes before the webinar begins on Thursday, June 20, 2019, please click the link below to join the webinar:
https://zoom.us/j/628944137external icon

Or iPhone one-tap :
US: +16468769923,,628944137# or +16699006833,,628944137#

Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923 or +1 669 900 6833

Webinar ID: 628 944 137
International numbers available: https://zoom.us/u/anixAVglVexternal icon

WC2922 0387-0000-19-124-L04-P (must be completed by July 22, 2019)
WD2922 0387-0000-19-124-H04-P (must be completed by July 23, 2021)

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians
  • Contact Information:coca@cdc.gov
  • Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
  • Method of Participation:You may participate in the educational activity by viewing the program information above.
  • Fees: Continuing Education (CE) is free.

Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

Image of acpe logo.CPE:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-19-124-L04-P and enduring 0387-0000-19-124-H04-P course category.

This activity has been designated as Knowledge-Based.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

AAVSB/RACE:This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

CDC did not accept commercial support for this continuing education activity.

Page last reviewed: April 1, 2019